EMA Authorised: Valdoxan (agomelatine) — Les Laboratoires Servier

View source ↗

Summary

The EMA authorised Valdoxan (agomelatine) for major depressive disorder, with Les Laboratoires Servier as the marketing authorisation holder; decision date 14/0…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Valdoxan (agomelatine)

Snippet

Status: Authorised. Therapeutic area: Depressive Disorder, Major. MAH: Les Laboratoires Servier. Decision date: 14/04/2025